News
Market and company headlines
CYTKAll
Loading
11:00-17:00Oct 192 Stories
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 15, 2026 it granted stock options to purchase an aggregate of 60,465 shares of common stock and 40,084 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 29 employees, whose employment commenced in September and October 2026 as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the R
BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says
BridgeBio Pharma (BBIO), Madrigal Pharmaceuticals (MDGL) and Cytokinetics (CYTK) traded meaningfully
07:00-09:00Oct 192 Stories
Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?
Cytokinetics' Myqorzo gains commercial traction with growing prescriptions, international launches and promising clinical data that could expand its market opportunity.
Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Health Canada has issued a Notice of Compliance authorizing MYQORZO® (aficamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) class II-III in adult patients. MYQORZO is a once-daily, oral allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition wit
03:00-07:00Oct 192 Stories
HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $140 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $140 price target.
Cytokinetics Receives Notice Of Compliance From Health Canada Authorizing Treatment Use Of MYQORZO For Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Health Canada has issued a Notice of Compliance authorizing MYQORZO® (aficamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy
06:00Oct 161 Story
12:00Oct 151 Story
07:00-09:00Oct 22 Stories
Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?
Bristol Myers' Camzyos gains a broader FDA label and strong sales growth, while emerging competitors and pipeline setbacks shape its cardiovascular outlook.
Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four upcoming presentations, including two Late Breaking Clinical Research presentations and two oral presentations, at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 taking place in Phoenix, AZ from October 9 – 12, 2026. Late-Breaking Clinical Trial Presentations Title: Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Res
07:00-11:00Sep 302 Stories
Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More
Lexicon Pharmaceuticals, Inc. upgraded to Buy as multiple near-term catalysts emerge across its pipeline. Click for this updated look at LXRX.
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Multi-center Prospective Study to Track Real-World Safety, Clinical Effectiveness, and Healthcare Resource Impact of MYQORZO in Routine Clinical Practice SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the start of ASPEN-HCM (Aficamten Study of Patient Experience and Novel Outcomes in Symptomatic Obstructive HCM), a prospective, multicenter, observational real-world study evaluating MYQORZO® (aficamten) in adult patients w
03:00Sep 301 Story
10:00-13:00Sep 252 Stories
Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach
B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for the sector during the Q3 2026 earnings season.
Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference
Cytokinetics (NASDAQ:CYTK) executives outlined the company’s commercial expansion plans, cardiovascular pipeline and business-development priorities during a Bernstein investor symposium, highlighting the launch of MYQORZO and clinical programs targeting several forms of heart failure. Isaac Ciecha
09:00Sep 231 Story
07:00Sep 211 Story
16:00Sep 171 Story
06:00-08:00Sep 142 Stories
Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program
Program Provides Communications and Outreach Support for Patient Advocacy Organizations Focused on Cardiovascular Diseases Deadline for Applications is October 2, 2026 SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the ninth annual Cytokinetics Communications Grant Program. The program will award a number of grants to patient advocacy organizations serving the hypertrophic cardiomyopathy (HCM) and
Cytokinetics, Incorporated (CYTK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Cytokinetics, Incorporated (CYTK) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 7:45 AM EDTCompany ParticipantsRobert I.
05:00Sep 141 Story
07:00Sep 111 Story
12:00Sep 101 Story
08:00Aug 201 Story
15:00Aug 191 Story
17:00Aug 181 Story
05:00Aug 141 Story
10:00-19:00Aug 132 Stories
Cytokinetics (CYTK) Q2 2026 Earnings Call Transcript
MYQORZO captures 40% new-to-brand share with 1,500 dispensed patients.
Barclays Maintains Overweight on Cytokinetics, Raises Price Target to $110
Barclays analyst Emily Field maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $95 to $110.
05:00-08:00Aug 132 Stories
JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $103
JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $97 to $103.
Cytokinetics Files Delaware U.S. District Court Claim Against Bristol-Myers Squibb And MyoKardia Seeking Judgment That CYTK Isn't Infringing U.S. Patent No. 12,616,697 And That The ’697 Patent Claims Are Invalid
In the complaint, the Company requests, among other things: a judgment declaring that the Company does not infringe and has not infringed any valid claim of the ’697 patent; a judgment declaring that the claims of the